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Certain gliomas often harbor a mutation in the activity center of IDH1 (R132H), which leads to
the production of the oncometabolite 2-R-2-hydroxyglutarate (2-HG). In six model systems,
including patient-derived stem cell-like glioblastoma cultures, inhibition of Bcl-xL induces
significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. Anaplastic
astrocytoma samples with mutated IDH1 display lower levels of Mcl-1 than IDH1 wild-type
tumors and specific knockdown of Mcl-1 broadly sensitizes glioblastoma cells to Bcl-xL
inhibition-mediated apoptosis. Addition of 2-HG to glioblastoma cultures recapitulates the
effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and
reduces ATP levels in glioblastoma cells. 2-HG-mediated energy depletion activates AMPK
(Threonine 172), blunting protein synthesis and mTOR signaling, culminating in a decline
of Mcl-1. In an orthotopic glioblastoma xenograft model expressing mutated IDH1, Bcl-xL
inhibition leads to long-term survival. These results demonstrate that IDH1-mutated gliomas
are particularly vulnerable to Bcl-xL inhibition.
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G lioblastoma and diffuse gliomas in general remainincurable diseases despite extensive efforts to identifymore effective treatment paradigms. The era of persona-
lized medicine has the potential to revolutionize our under-
standing of malignant neoplasms and to broadly influence
therapeutic decision-making. Deep-sequencing technologies have
greatly assisted in the identification of novel mutations in cancers.
Examples are mutations of IDH1 at codon 132 (R132H) and
IDH2 at codon 172 (R172K) in diffuse gliomas and acute myeloid
leukemia. The majority of low-grade gliomas and secondary
glioblastomas harbor the IDH1 mutation1. While glioblastomas
are histologically and molecularly heterogeneous, when present,
the IDH1 (R132H) mutation is seen in virtually all glioma cells
throughout the entire tumor. IDH1- and IDH2-mutated tumors
display significantly elevated levels of 2-R-2-hydroxyglutarate
(2-HG). While the initial discovery of IDH mutations raised
significant excitement in the field, the identification of 2-HG in
IDH-mutated tumors received as much attention due to the
potential translational implications2, 3.
Anti-apoptotic Bcl-2 family members, such as Bcl-xL and Mcl-
1, are highly expressed in human glioblastomas and, therefore, it
is conceivable that interference with these molecules might exert
significant anti-glioblastoma activity. Recent advances in the
design of small molecules led to the discovery of BH3-mimetics,
such as ABT263. Unfortunately, not all tumors are equally
sensitive and it remains pivotal to unravel predictive biomarkers
that identify patients with tumors that would especially benefit
from the administration/addition of a BH3-mimetic. For exam-
ple, Mcl-1 is a major mediator of BH3-mimetic resistance.
In this report, we demonstrate that inhibition of Bcl-xL causes
synthetic lethality in IDH1-mutated glioblastoma cells in vitro
and in vivo and that these effects are mediated by the oncome-
tabolite, 2-HG, which reduces Mcl-1 protein levels. Consistently,
our findings reveal that IDH1-mutated gliomas display lower
protein levels of Mcl-1.
Results
IDH1-mutated glioblastoma cells are more responsive to Bcl-
xL inhibition. Transduced U87MG and T98G glioblastoma cells,
bearing the wild-type or mutated form of IDH1 were treated with
increasing concentrations of the BH-3 mimetic ABT263, a known
inhibitor of both Bcl-xL and Bcl-2. U87MG (IDH1-R132H) cells
displayed an approximately thirty times higher sensitivity
to ABT263 (IC50= 0.1195 μM—nanomolar range) than their
wild-type counterparts (IC50= 3.314 μM) (Fig. 1a). Similarly, in
T98G glioblastoma cells treatment with ABT263 resulted in
a significantly stronger anti-proliferative response among IDH1-
mutated cells moving the respective IC50-values into the lower
nanomolar range (Fig. 1b).
To gain further insight on how general this biological
observation is we extended our studies to an isogenic model
using HCT116 (IDH1-WT/IDH1-R132H) colorectal cancer
cells and two patient-derived IDH1-R132H expressing glioma
stem-like cells, NCH612 and BT-142. In concordance with our
findings in the virally transduced glioblastoma cell lines, HCT116
IDH1-R132H cells (heterozygous knock-in mutation) showed
higher sensitivity to ABT263 with a threefold decrease of the
IC50 value (Fig. 1c). In a similar manner, NCH612 and BT-142
IDH1-R132H-positive glioma stem-like cells showed a high
susceptibility toward ABT263 treatment as reflected by nanomo-
lar IC50-values (Fig. 1d, e). IC50-values for ABT263 in glioma
stem-like cells bearing IDH1-WT or IDH1-R132H are displayed
in Supplementary Table 1. Next, we addressed the question
whether the oncometabolite 2-HG contributed to the ABT263-
mediated synthetic lethality seen in IDH1-R132H-expressing
cells. U87MG, T98G, LN229, SF188 (pediatric), MGPP-3 (mouse)
glioblastoma cells, NCH644 glioma stem-like cells and GBM12
(derived from a patient-derived xenograft) glioma cells were
treated with ABT263, 2-HG, the combination of both or vehicle.
Across all cell lines tested, the combination treatment resulted
in a synergistic anti-proliferative effect (Fig. 1g–n and Supple-
mentary Table 2). To gain a deeper understanding of the
molecular mechanism(s) responsible for the preferential response
of IDH1-mutated cancer cells to ABT263 treatment, we
performed knockdown experiments with small-interfering RNA
(siRNA) against Bcl-xL, a known major target of ABT263.
Knockdown of Bcl-xL resulted in a significant increase in
the subG1 fraction of U87MG IDH1-R132H and HCT116
IDH1-R132H cells when compared to the respective IDH1
wild-type cells (Fig. 2a, b). Moreover, treatment with the relatively
selective Bcl-2 inhibitor ABT199 did not result in a difference in
response among HCT116 IDH1-WT or HCT116 IDH1-R132H
cells, emphasizing the predominant role of Bcl-xL in this context
(Supplementary Fig. 1A). We next examined whether the
synergistic anti-neoplastic activity of ABT263 and 2-HG can be
attributed to selective inhibition of Bcl-xL. We, therefore, silenced
U251 and LN229 glioblastoma cells for Bcl-xL. In both cell lines,
knockdown of Bcl-xL resulted in a significant decrease in the
fraction of viable cells among those cells treated in addition
with 2-HG (Fig. 2c, d). In addition, treatment with the Bcl-2
inhibitor ABT199 did not result in a marked enhancement of the
pro-apoptotic response in SF188, U251 and LN229 cells treated
with ABT199/2-HG when compared to single-agent treatments
(Supplementary Fig. 1B–D).
Presence of an IDH1-mutated genotype and 2-HG sensitizes
for BH-3 mimetic-mediated apoptosis. We next addressed the
mechanism responsible for the enhanced anti-proliferative
response toward ABT263 treatment in IDH1-mutated cells.
Analysis of cell morphology lead to the observation that cells
carrying the IDH1-R132H mutation developed typical features of
apoptosis upon treatment with ABT263. In line with this finding,
IDH1-mutated U87MG cells treated with ABT263 showed
a significantly increased fraction of annexin V-positive
cells (apoptotic cells) (Fig. 2e). Similarly, in IDH1-mutated
T98G glioblastoma cells, PICPG-4 glioma cells (IDH1-R132H + ,
PDGF + , TP53−/−; derived from a transgenic mouse model) and
isogenic HCT116 IDH1-R132H cells treatment with ABT263
resulted in an enhanced fraction of subG1 cells (apoptotic cells)
when compared to T98G IDH1-WT, PPC2 (IDH1-WT) or
HCT116 IDH1-WT cells (Fig. 1f and Supplementary Fig. 2A, B).
On the molecular level, these findings were mirrored by enhanced
cleavage of caspases 3, 9 and PARP in IDH1-mutated U87MG,
T98G and HCT116 cells (Fig. 2g and Supplementary Fig. 2C, D).
Microscopic analyses of glioblastoma cells treated with ABT263
in the presence of 2-HG revealed morphological changes typically
associated with apoptosis (Fig. 1n). We, therefore, conducted flow
cytometric analyses to elucidate whether the mechanism
responsible for the anti-proliferative activity of a combined
treatment with 2-HG and ABT263 involves the induction of
apoptosis. As anticipated, treatment with ABT263 and 2-HG
resulted in a synergistic increase in the fraction of annexin
V-positive (apoptotic) U87MG, LN229, T98G, and SF188
glioblastoma cells and the fraction of subG1 cells in SF188
pediatric glioblastoma cells (Fig. 2h and Supplementary
Fig. 3A–C). Consistent with this finding, LN229 and SF188
glioblastoma cells treated with ABT263 in the presence of 2-HG
show a markedly enhanced cleavage of caspases 9, 3, and PARP,
supporting the relevance of apoptosis as mechanism of the
synergistic anti-cancer activity (Fig. 2j). To address whether the
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preferential pro-apoptotic response in IDH1-mutated cells
toward ABT263 is at least in part mitochondrially driven,
we performed staining for JC-1. IDH1-mutated U87MG
glioblastoma cells showed a marked decrease in the mitochon-
drial membrane potential when subjected to treatment with
increasing concentrations of ABT263 when compared to
U87MG IDH1-WT cells (Fig. 2f). This finding supports at least
a partial contribution of the mitochondrial pathway to the
pro-apoptotic response. In support of this finding, treatment
with the death receptor ligand TRAIL did not result in enhanced
pro-apoptotic response in IDH1-mutant cells (Supplementary
Fig. 4A–E). Furthermore, pro-apoptotic chemotherapeutics
such as etoposide or paclitaxel did not display a varying
response dependent on different IDH1 genotypes (Supplementary
Fig. 4F, G).
Because ABT263 is a known inhibitor of the anti-apoptotic
Bcl-2 family members Bcl-2 and Bcl-xL, we next examined
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treatment would be at least in part be mitochondrially driven.
We performed staining for JC-1 to detect changes in the
mitochondrial membrane potential. As shown in Fig. 2i, treat-
ment with ABT263 in the presence of 2-HG resulted in a marked
increase in the fraction of LN229 glioblastoma cells undergoing a
loss of the mitochondrial membrane potential.
Mcl-1 is downregulated in IDH1-mutated glioblastoma cells
and patient tumor samples. We next examined how the presence
of the IDH1 mutation affects the expression of pro- and
anti-apoptotic Bcl-2 family proteins. As shown in Fig. 3c and
Supplementary Fig. 5A and B, U87MG and murine glioblastoma
cells bearing the IDH1 mutation showed decreased expression of
Mcl-1, Bcl-xL, and Bcl-2.
Compensatory upregulation of Mcl-1 is a well-defined
mechanism of resistance toward ABT263. To extend our
molecular studies to a more biologically relevant and disease-
related paradigm, we determined basal Mcl-1 protein expression
along with other anti- and pro-apoptotic Bcl-2 family members in
tumor samples from patients with anaplastic astrocytoma
stratified according to the presence or absence of the IDH1-
R132H mutation. In IDH1-mutated tumor samples Mcl-1
expression was significantly decreased, suggesting a broad
biological applicability of this observation (Fig. 3a, b). In contrast,
no significant difference was found with respect to Bcl-2 or Bcl-xL
expression among different IDH1 mutation status (Supplemen-
tary Fig. 5C).
To address the biological relevance of Mcl-1 as a driver for
resistance toward ABT263, we performed knockdown experi-
ments. U87MG and LN229 glioblastoma cells silenced for Mcl-1
by four different siRNAs showed a marked increase in the
fraction of sub-G1 cells when treated with ABT263 (Fig. 3f, g).
Noxa and Bak are the main Mcl-1 interacting pro-apoptotic
Bcl-2 family proteins. To elucidate whether Noxa is of importance
for the synergistic pro-apoptotic effect of ABT263 and 2-HG, we
performed knockdown experiments. Silencing Noxa results in a
significant inhibition of ABT263/2-HG-mediated apoptosis
(Fig. 3h and Supplementary Fig. 5D).
Mcl-1 sequesters the pro-apoptotic multi-domain effector
protein Bak4. Once Noxa binds to Mcl-1, Bak is released4.
Given that 1) the Noxa/Mcl-1 ratio is markedly increased
upon treatment with AB263/2-HG and 2) Noxa knockdown
results in an attenuation of the pro-apoptotic response, one
would expect that knockdown of Bak also attenuates ABT263/2-
HG-mediated apoptosis. As anticipated, selective knockdown
of Bak resulted in a significant reduction of apoptosis in cells
treated with ABT263 and 2-HG (Fig. 3i and Supplementary
Fig. 5E).
Based on our observation that in IDH1-mutated glioblastoma
cells Mcl-1 expression is decreased, we next examined whether
2-HG treatment would recapitulate this molecular feature. Both
U87MG and GBM12 cells displayed a concentration-dependent
decrease in Mcl-1 expression when treated with 2-HG for 24 h
(Fig. 3d, e). To further assess the subjacent mechanism, we
performed real-time rtPCR experiments. Mcl-1 messenger RNA
(mRNA) expression was not decreased but even increased in
U87MG cells suggesting a post-transcriptional mechanism
(Supplementary Fig. 5F).
Mutant IDH1 R132H and 2-HG blunt oxidative energy
metabolism. To determine the underlying mechanism of reduced
Mcl-1 protein levels in IDH1 mutant cells, we conducted
transcriptome analysis with subsequent gene set enrichment
analysis. We found that U87 IDH1-mutated glioblastoma cells
displayed a reduction in genes related to oxidative metabolism,
including cellular respiration, tricarboxylic acid (TCA) cycle, and
pyruvate metabolism (Fig. 4a, b and Supplementary Fig. 6A)). To
address this finding, we analyzed the basal oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR) in wild-
type and mutant IDH1 cells. (Fig. 4c). Based on these findings, we
analyzed the metabolic phenotype of IDH1 wild-type and IDH1
R132H-mutated glioblastoma cells. Our findings suggest that the
IDH1 mutation leads to a metabolic shift with enhanced glyco-
lysis and reduced oxidative phosphorylation (Fig. 4c), supporting
the findings observed in the transcriptome analysis. In agreement,
IDH1 R132H-mutated or 2-HG-treated glioblastoma cells
showed less mitochondrial respiration and significant reduction
in ATP production (Fig. 4d–g). As early as one hour after
treatment with 1 mM 2-HG, glioblastoma cells had a significant
reduction in baseline respiration, maximum respiratory capacity,
spare capacity, and ATP production (Supplementary Fig. 7A–C).
These findings suggest that 2-HG has a direct impact on
mitochondrial respiration (Supplementary Fig. 7). Consistently,
total ATP levels were also reduced in 2-HG-treated and IDH1
R132H-mutated cells (Supplementary Fig. 6B). To test the
hypothesis that ATP depleting reagents are capable of enhancing
ABT263-mediated cell death, glioblastoma cells were treated with
two bona-fide ATP reducing compounds, Oligomycin and 2-DG.
In the presence of ABT263, both molecules dramatically
enhanced the reduction of cellular viability as compared to each
compound on its own (Fig. 4h and Supplementary Fig. 6C). Since
ATP levels affect cellular survival, we determined as to whether or
Fig. 1 IDH1-R132H-mutated cells are more susceptible to treatment with ABT263. a U87MG glioblastoma cells were transduced with pLPCX IDH1-WT or
IDH1-R132H prior to treatment with increasing concentrations of ABT263 for 72 h. Cellular viability was determined by MTT assay and the IC50-values
were calculated based on a non-linear regression analysis. Data are presented as mean and SD, n= 3. b T98G glioblastoma cells were transduced with
pLPCX IDH1-WT or IDH1-R132H prior to treatment with increasing concentrations of ABT263 for 72 h. Cellular viability was determined by MTT assay and
IC50-values were calculated. Data are presented as mean and SD, n= 3. c HCT116 IDH1-WT/IDH1-R132H cells were treated with increasing concentrations
of ABT263 for 72 h. Cellular viability and IC50-values were determined based on MTT assay. Data are presented as mean and SD, n= 3.
d, e NCH612 (IDH1-R132H) (d) and BT-142 (IDH1-R132H) (e) glioma cells were subjected to treatment with increasing concentrations of ABT263 for 72 h.
Cellular viability and IC50-values were determined by CelltiterGlo assay. Data are presented as mean and SD, n= 3. f PPC-2 (IDH1-WT) and PICPG-4
(IDH1-R132H) glioma cells were treated for 48 h with solvent or ABT263 as indicated. Staining with propidium iodide was performed and the fraction
of viable cells (100%-SubG1 cells) was determined by flow cytometry. Column: mean. Error bar, SD (n= 3). g–j T98G (g), LN229 (h), SF188 i and MGPP-3
(j) glioblastoma cells were treated for 72 h with solvent, ABT263, 2-HG or the combination of both prior to determining cellular viability by MTT assay.
Column: mean. Error bar: SD, n= 3. k–m U87MG cells (k), NCH644 glioma stem-like cells (l) and GBM12 patient-derived xenograft cells (m) were treated
for 72 h with indicated combinations of ABT263 and 2-HG. Normalized isobolograms were calculated using the CompuSyn software (ComboSyn, Inc.,
Paramus, NJ). Data points located on the line indicate an additive drug–drug interaction. Data points located below the line indicate a synergistic drug–drug
interaction and data points above the line indicate an antagonistic drug–drug interaction. n Representative microphotographs are provided for SF188
pediatric glioblastoma cells treated for 24 h with solvent, ABT263 and 2-HG as indicated. Scale bar: 100 μm or 20 μm (microphotograph at higher
magnification)
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Fig. 2 Knockdown of Bcl-xL enhances apoptosis in IDH1-mutated cancer cells. a U87MG IDH1-WT/IDH1-R132H glioblastoma cells were transfected either
with non-targeting (n.t.)-siRNA or Bcl-xL-siRNA prior to staining with propidium iodide and flowcytometric analysis, n= 3. Knockdown of Bcl-xL was
confirmed by western blot analysis. b HCT116 IDH1-WT/IDH1-R132H cells were transfected either with (n.t.)-siRNA or Bcl-xL-siRNA prior to staining with
propidium iodide and flowcytometric analysis. n= 3. Knockdown of Bcl-xL was confirmed by capillary electrophoresis. c U251 glioblastoma cells were
treated with (n.t.)-siRNA or Bcl-xL-siRNA in the presence or absence of 2-HG for 24 h. Staining for propidium iodide was performed. n= 3. Bcl-xL knock-
down was confirmed by performing western blot analysis for Bcl-xL. d LN229 glioblastoma cells were treated with (n.t.)-siRNA or Bcl-xL-siRNA in the
presence or absence of 2-HG for 24 h. Staining for propidium iodide was performed. n= 3. Bcl-xL knock-down was confirmed by western blot analysis.
e U87MG IDH1-WT/IDH1-R132H glioblastoma cells were treated for 72 h with increasing concentrations of ABT263 (concentrations in μM) or solvent
prior to staining with annexin V/propidium iodide and flowcytometry. n= 3. f U87MG IDH1-WT/IDH1-R132H cells were treated for 72 h with ABT263 or
solvent as indicated prior to staining for JC-1 and flowcytometry. A quantitative representation of the fraction of red plus green fluorescent cells vs. green-
only fluorescent cells is displayed. n= 3. g U87MG IDH1-WT/IDH1-R132H glioblastoma cells were treated for 7 h with increasing concentrations of
ABT263 or solvent. Whole-cell extracts were collected and western blot analysis was performed for caspase 9 (CP9), cleaved caspase 3 (cCP3), PARP and
Actin. h Representative flow plots of LN229 glioblastoma cells that were treated for 48 h with solvent, ABT263 and 2-HG as indicated. Staining for annexin
V/propidium iodide was performed prior to flowcytometric analysis. i Representative flow plots (JC1-staining) of LN229 glioblastoma cells treated for 48 h
with solvent, ABT263 and 2-HG as indicated. j LN229 and SF188 glioblastoma cells were treated for 7 h with solvent, ABT263 and 2-HG. Western blot
analysis is shown for caspase 9 (CP9), cleaved caspase 3 (cCP3), cleaved PARP (cPARP) and Actin. Columns: mean. Error bars: SD
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Fig. 3 Mcl-1 is downregulated in IDH1-mutated gliomas. a Protein was extracted from human tumor samples of anaplastic astrocytoma expressing IDH1-
WT or IDH1-R132H. Western blot analysis was performed for Mcl-1, Bcl-xL, Bcl-2, Noxa, and Bim. Actin served as loading control. b Scatter plot
demonstrating Mcl-1 protein expression among IDH1-WT (n= 5) and IDH1-R132H (n= 6) expressing anaplastic astrocytoma samples. Densitometric
analysis was performed using imageJ 1.47 v (http://imagej.nih.gov/ij). Pixel density was normalized to the respective Actin control. c Whole-cell extracts
of U87MG IDH1-WT/IDH1-R132H cells were collected to determine base line protein expression of Mcl-1, Noxa, Bcl-2, Bcl-xL, and BIM by western
blot analysis. Actin was used to ensure equal loading. d, e U87MG glioblastoma cells (d) and GBM12 patient-derived glioblastoma xenograft cells (e) were
treated for 3 h (U87MG) or 24 h (GBM12) with increasing concentrations of 2-HG. Whole-cell extracts were collected prior to performing western
blot analysis for Mcl-1, Bcl-2, and Bcl-xL. Western blot for Actin or 14-3-3 was performed to confirm equal loading. f, g U87MG (f) and LN229 (g) cells
were treated with non-targeting (n.t.)-siRNA or 4 different Mcl-1-siRNAs and subjected to treatment with solvent or ABT263, for 24 h. Staining for
propidium iodide was performed prior to flowcytometry. The fraction of subG1 cells was determined. Column: mean. Error bar: SD, n= 3. Western blot
analysis was performed to confirm Mcl-1 knockdown. h, i Quantitative representation of LN229 cells treated with non-targeting (n.t.)-siRNA, Noxa-siRNA
(h) or Bak-siRNA (i) prior to treatment with ABT263/2-HG or solvent. Staining for propidium iodide and flowcytometry were performed to determine the
fraction of subG1 cells. Column: mean. Error bar: SD, n= 3. Whole-cell extracts were collected and western blot analysis was performed for Noxa and Bak to
confirm appropriate knockdown
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not Oligomycin and 2-DG are capable of reducing Mcl-1 protein
levels. Our findings suggest that Oligomycin and 2-DG suppress
Mcl-1 protein levels (Fig. 4i), explaining in part why ABT263-
synergizes with these two compounds.
Mutated IDH1 and 2-HG lead to a reduction of protein
synthesis and mTORC1 signaling. Reduction in ATP-levels is
associated with cellular stress and a subsequent reduction in
protein synthesis. To further evaluate this hypothesis, we
performed sunset assays5. As shown in Fig. 5a, U87MG IDH1-
R132H cells treated with puromycin show a significantly
decreased puromycin labeling when compared to IDH1-WT cells
confirming decreased protein synthesis.
Moreover, U87MG cells treated with increasing concentrations
of 2-HG show a marked decrease in puromycin signal, which
indicates a decrease in translational activity (Fig. 5b).
Mammalian target of rapamycin (mTOR) signaling represents
an important regulator of cellular proliferation in cancer. To link
mTOR signaling with low energy levels, we analyzed the
phosphorylation status of AMPK. IDH1-mutated U87MG
glioblastoma and NCH644 glioma stem-like cells display
significantly enhanced phosphorylation of AMPK (Fig. 5c and
Supplementary Fig. 6D). To confirm whether mTOR signaling is
affected in IDH1-mutated glioblastoma cells, we performed
western blot analyses for p-mTOR and its downstream effector
p-S6. In IDH1-mutated U87MG cells, mTOR signaling was
significantly downregulated (Fig. 5d). Moreover, phosphorylation
of 4EBP1 was found to be decreased. Furthermore, we found that
glioblastoma cells treated with, 2-HG, Oligomycin, and 2-DG
showed an increase of phosphorylation of AMPK (Fig. 5e),
suggesting lower levels of ATP. In turn, active AMPK blunts the
activity of mTORC1.
Consequently, in U87MG and GBM12 cells, treatment with
2-HG resulted in a significant decrease in p-mTOR and p-S6
expression (Fig. 5f, g, Supplementary Fig. 8A).
To further address whether alterations in proteasomal
degradation of Mcl-1 add to the post-translational mechanism
we treated U87MG cells with 2-HG in the presence or absence
of the proteasome inhibitor MG132. Combined treatment with

























































































































































































Fig. 4 U87-mutated IDH1 R132H status and the onco-metabolite 2-HG impair oxidative mitochondrial metabolism, suppressing ATP and rendering cells
vulnerable to Bcl-xL inhibition, a, b U87 wild-type and IDH1 R132H-mutated glioblastoma cells were submitted for transcriptome analysis and subsequently
analyzed by GSEA. Shown are GSEA plots with the respective statistical analysis. These results suggest an impairment of oxidative metabolism with
downregulation of SDHD, IDH3A, PDHX, and DLAT. c Wild-type or IDH1 R132H-mutated glioblastoma cells were analyzed for oxygen consumption
rate (OCR) or extracellular acidification rate (ECAR) by Seahorse XFp Flux analyzer (metabolic phenotype analysis). Column: mean. Error bar: SD, n= 3.
d Wild-type and IDH1 R132H-mutated glioblastoma cells were analyzed for mitochondrial oxygen consumption rate. Column: mean. Error bar: SD, n= 3.
e Wild-type and IDH1 R132H-mutated glioblastoma cells were analyzed for relative oxidative phosphorylation mediated ATP production. Column: mean.
Error bar: SD n= 3. f, g U87 cells were treated with vehicle or 1 mM 2-HG and analyzed as in e, f. Column: mean. Error bar: SD, n= 3. h U87 cells were
treated with 1 μM ABT263, 5 μM Oligomycin or the combination of both. Subsequently, cells were analyzed by CellTiter-Glo® assay. Column: mean.
Error bar: SD, n= 3. i U87 cells were treated with 2-DG or oligomycin with the indicated concentrations and analyzed by capillary electrophoresis for the
expression of Mcl-1 and Vinculin, using the Wes instrument. Student’s t-test or one-way ANOVA with post-hoc Tukey analysis were used for statistical
analysis and a p-value of <0.05 was considered statistically significant
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that the 2-HG-mediated decrease in Mcl-1 is at least in part
mediated by enhanced proteasomal degradation (Supplementary
Fig. 8B). Finally, Mcl-1 mRNA levels did not decrease in the
presence of 2-HG (Supplementary Fig. 5F), confirming a
predominantly post-transcriptional regulation of Mcl-1.
ABT263 prolongs survival in an orthotopic IDH1-mutated
glioblastoma xenograft model. Our in vitro data showed an
enhanced anti-neoplastic activity of ABT263 in IDH1-mutated
glioblastoma cells. We next examined whether this finding
also translates into enhanced therapeutic efficacy in vivo. In a
heterotopic subcutaneous glioblastoma model, animals with
U87MG IDH1-R132H tumors subjected to treatment with
ABT263 had a significantly decreased tumor growth rate
and even showed tumor regression when compared to vehicle
treatment (Fig. 6e, f). In contrast, no significant difference in
tumor growth was noted between vehicle and ABT263-treated
animals with U87MG IDH1-WT tumors. Given that there was no
difference between non-treated and ABT263 IDH1 wild-type
U87MG skin xenograft tumors, we focused our intracranial
studies on the IDH1-R132H tumor cells. To this end, U87MG
IDH1-R132H glioblastoma cells were implanted intracranially
and allowed to form tumors. Once tumors formed, animals were
randomized to treatment with either vehicle or ABT263. In ani-
mals with tumors carrying the IDH1-mutation, treatment with
ABT263 resulted in a significantly prolonged overall survival
(Fig. 6a–d). After 103 days, all control animals were dead, while
three ABT263-treated animals (out of five) were still alive
(median survival vehicle animals: 40 days; median survival
ABT263-treated animals: > 103 days; p< 0.02).
We next assessed whether ABT263 also yields a stronger anti-
cancer activity in an IDH1 R132H-expressing isogenic tumor
model. For that purpose, IDH1 WT or IDH1 R132H HCT116
cells were implanted subcutaneously into nude mice. As shown
in Fig. 6g, h, treatment with ABT263 resulted in a marked
reduction of the tumor growth rate of both HCT116 IDH1
WT- as well as HCT116 IDH1 R132H-expressing tumors.
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Fig. 5 Impaired protein synthesis leads to downregulation of Mcl-1 in IDH1-mutated glioblastomas. a U87MG IDH1-WT/IDH1-R132H cells were
pretreated with puromycin. Whole-cell extracts were collected and capillary electrophoresis was performed for puromycin. Vinculin served as loading
control. Treatment with 10 μg ml−1 cycloheximide served as a negative control. Densitometric analysis was performed using imageJ 1.47 v (http://imagej.
nih.gov/ij). Pixel density was normalized first to the respective Vinculin and second to U87MG IDH1-WT cells. b U87MG cells were treated for 24 h with
increasing concentrations of 2-HG prior to incubation for 2 h with puromycin (10 μM). Treatment with the protein synthesis inhibitor cycloheximide (10 μg
ml−1) served as a negative control. Whole-cell extracts were collected prior to western blot analysis for puromycin. Densitometric analysis was performed
using imageJ 1.47 v (http://imagej.nih.gov/ij). Pixel density was determined and normalized first to the respective Actin signal and second to U87MG cells
treated with solvent. c Whole-cell extracts of U87MG IDH1-WT/IDH1-R132H cells were collected prior to capillary electrophoresis for p-AMPK
(Threonine 172) and AMPK. Vinculin served to control for equal loading. dWhole-cell extracts of U87MG IDH1-WT/IDH1-R132H cells were collected prior
to western blot analysis for p-mTOR, p-S6, and p-4EBP1. Western blot for Actin was performed to confirm equal loading. e U87MG and GBM12 cells
were treated for 48 h with 2-HG, oligomycin or 2-DG as indicated. Whole-cell extracts were collected prior to capillary electrophoresis for pAMPK and
AMPK. f, g U87MG (f) and GBM12 (g) cells were treated with 2-HG as indicated. Whole-cell extracts were collected. Western blot analysis or capillary
electrophoresis was performed for p-mTOR, mTOR, p-S6 and S6. Either Actin or Vinculin served as loading control
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tumors expressing the IDH1 mutation in animals treated with
ABT263 was significantly smaller when compared to tumors from
vehicle-treated animals. In contrast, the mean size of tumors
expressing the wild-type form of IDH1 did not significantly differ
between tumors from vehicle-treated and ABT263-treated
animals.
Next, we tested the efficacy of ABT263 in a patient-derived
xenograft model system of IDH mutant glioblastoma (GBM164).
After two weeks of treatment, Bcl-xL inhibition led to a
significant tumor regression (p< 0.001) (Fig. 7a, b).
Treatment with ABT263 results in prolonged survival in the
presence of 2-HG in vivo. To assess whether treatment
with ABT263 in the presence of 2-HG provides a survival benefit
in vivo, we used an orthotopic model of proneural glioblastoma6, 7.
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Fig. 6 ABT263 extends overall survival in an orthotopic glioblastoma model of IDH1-mutated U87MG. a U87MG IDH1-R132H cells were implanted into the
right striatum of Nude mice. After establishment of tumors, two groups were formed and animals were treated with either vehicle (n= 5; median survival
= 40 days) or three times per week with 100mg kg−1 ABT263 (n= 5; median survival> 108 days). Kaplan–Meier curves were generated for survival
analysis. Comparison of survival curves was performed using Log-rank (Mantel-Cox) test. b Representative histological brain section from a vehicle-treated
animal stained with H&E. Scale bar: 1 mm. c Immunohistochemical staining for IDH1-R132H in a tumor derived from U87MG IDH1-R132H cells.
Magnification, 40×. Scale bar: 50 µm. d Representative MRI images of vehicle treated and ABT263-treated animals carrying U87MG IDH1-R132H tumors.
e 1 × 106 U87MG IDH1-WT or IDH1-R132H cells were implanted subcutaneously. After tumor formation animals were randomized into two groups per
IHD1 status (n= 10 tumors per group) and treated intraperitoneally with vehicle or ABT263 100mg kg−1 3× per week. f Scatter plot indicating the tumor
size of animals treated as described for E on day 20 after tumor cell implantation. g In all, 1 × 106 HCT116 IDH1-WT or IDH1-R132H colorectal cancer cells
were implanted subcutaneously. After tumor formation animals were randomized into two groups per IDH1 status (n= 12 tumors per group) and treated on
5 consecutive days intraperitoneally with vehicle or ABT263 75mg kg−1. h Scatter plot indicating the tumor size of animals treated as described for h on
day 12 after tumor cell implantation. e–h Data are presented as mean and SEM e, g/SD, f, h). Student’s t-test was used for statistical analysis and a p-value
of <0.05 was considered statistically significant
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Intracranial tumors (PDGF + , PTEN−/−, p53−/−, luciferase + )
were induced through retroviral injection and tumor formation
was verified by IVIS imaging (Fig. 7c–f). Convection-enhanced
delivery was used for local application of 2-HG in order to mimic
its local distribution as seen in IDH1-mutant tumors. Therefore,
2 weeks after injection of the virus micro-osmotic pumps were
placed to infuse 2-HG or vehicle intracranially for 7 days
accompanied by intra-peritoneal treatment with ABT263 or
vehicle. Delivery of 2-HG was verified by detecting Gadolinium
signal in magnetic resonance imaging (MRI) scans (Fig. 7e). As
shown in Fig. 7d, treatment with ABT263 provided a statistically
significant survival benefit in the presence of 2-HG. This obser-
vation was accompanied by a smaller tumor size and a weaker
luminescence signal (Fig. 7f).
Discussion
In low-grade gliomas and IDH-mutant glioblastomas, mutations
in IDH1 and less commonly in IDH2 predict significantly
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Fig. 7 Treatment with ABT263 in combination with 2-HG prolongs survival in a mouse model generated by orthotopic injection of PDGF-IRES-Cre
retrovirus. a GBM164 cryomush was implanted subcutaneously. After tumor formation, animals were randomized into two groups (n= 4–5 tumors per
group) and treated intraperitoneally with vehicle or ABT263 75mg kg−1 three times a week. b Scatter plot indicating the tumor size of animals treated as
described for a on day 14 after tumor cell implantation. a, b Data are presented as mean and SD. c Representative microphotograph of a tumor bearing
brain from a mouse treated with vehicle (H&E, 2× magnification) and microphotograph at higher magnification. Arrow heads indicate the formation of
pseudopalisading necrosis. Scale bar: 50 µm. d Kaplan–Meier curves of animals treated with vehicle (n= 5; median survival= 26 days), ABT263
intraperitoneally 100mg kg−1 3× per week (n= 5; median survival= 23 days), 10 mM 2-HG by convection-enhanced delivery for 7 days (n= 5; median
survival= 24 days) or ABT263 and 2-HG combined (n= 6; median survival= 28.5 days). Statistical comparison of survival curves was performed using
Log-rank (Mantel-Cox) test. e Sequential representative brain MRI scans showing the intracerebral accumulation of Gadolinium after convection-enhanced
delivery (Bruker ICONTM, 1 Tesla MR imager). f Sequential representative brain MRI scans of animals treated as indicated and described in d using a Bruker
BioSpecTM, 9.4 Tesla MR imager. Interrupted yellow linemarks the tumor outline. Representative photographs visualizing the bioluminescent signal emitted
by formed tumors after intraperitoneal injection of 150mg kg−1 D-Luciferin (GOLD Biotechnology, St Louis, MO) using an IVIS Spectrum optical imaging
system (Perkin Elmer, Waltham, MA)
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glioblastomas. While IDH1 is localized in the cytoplasm,
IDH2 resides in the mitochondria8. In contrast to IDH3, which
is localized to the mitochondria, utilizes NADH2 and is
reversible, both IDH1 and IDH2 catalyze a reaction that is
irreversible, which leads to the generation of NADPH2 and alpha-
ketoglutarate. In turn, NADPH2 may aid in entertaining an
anabolic state of cancer cells by providing electrons for certain
steps in metabolic synthesis, such as fatty acid and nucleotide
synthesis (ribonucleotide reductase). In IDH1-mutated tumors,
NADPH2 is a co-factor for the reduction of alpha-ketoglutarate to
2-HG. 2-HG accumulates to significant levels in IDH-mutated
glioblastomas, reaching up to 30 mM. Due to its structural
similarity to alpha-ketoglutarate 2-HG interferes with the
normal function of dioxygenases that require alpha-ketoglutarate
as a co-factor9. These dioxygenases are especially relevant in
histone and DNA demethylation, which ultimately leads to a
hypermethylated phenotype in IDH1-mutated neoplasms10.
Given its abundant presence in IDH1-mutated tumors, 2-HG is
being evaluated as a biomarker in imaging studies, serum and
urine of patients, which allows monitoring disease progression.
Given all these features of 2-HG, it was tempting to find inhibi-
tors that block the neo-enzymatic activity of mutated IDH
enzymes. One of these inhibitors is AGI-5198, which in model
systems of IDH1-mutated glioblastomas caused a significant
reduction in the levels of 2-HG11. Other groups have taken
similar approaches in other tumor entities as well12.
In this study, we utilized the concept of synthetic lethality
to efficiently target glioblastomas bearing the IDH1 mutation.
This strategy might be a welcome contribution for the treatment
of IDH-mutated neoplasms for several reasons, including the
notion that IDH inhibitors might not be efficient in every patient
with an IDH mutation and the concern of targeting a mutated
enzyme that confers a better prognosis. Concerning
immunotherapy, such approaches might only be feasible for
IDH1-mutated low-grade gliomas, but not suitable for high-grade
tumors. Despite the fact that glioblastomas are heterogeneous, the
IDH1 mutation is uniformly present within a mutated tumor13,
suggesting that “synthetic lethality”-based treatment approaches
should affect the majority of cancer cells within IDH-mutated
tumors. Our findings suggest that in solid tumors, such as
glioblastomas, the inhibition of Bcl-xL elicits synthetic lethality in
IDH1-mutated neoplasms. We utilized several experimental
approaches to verify this observation, including patient-derived
IDH1-mutated sphere cultures, isogenic cell cultures and
cells that were transfected or transduced with either wild-type
IDH1 or mutated IDH1 R132H. This plethora of model
systems is necessary since isogenic cells might not have the
classical genetic background in which IDH1 mutation usually
arise. All model system unequivocally confirmed that IDH1
R132H renders tumor cells more prone to the effects of inhibition
of Bcl-xL either by siRNA or pharmacologically through the
BH3-mimetic, ABT263. It is interesting to note that the “specific”
Bcl-2 inhibitor, ABT199, did not mediate synthetic lethality in
IDH1-mutated cells. Similar results were seen with knockdown
experiments, involving Bcl-2 alone. Our findings extend previous
studies of glioblastomas indicating a special role for mutated
IDH1 to modulate cell death pathways, such as autophagy and
apoptosis8, 14, 15. Our mechanistic findings are in contrast to an
earlier report, which suggested that in non-solid tumors (myeloid
leukemia) Bcl-2 antagonism is synthetically lethal with mutated
IDH1 or IDH216. Related research has indicated that solid tumors
are generally more dependent on Bcl-xL than on Bcl-2, which is
in agreement with our observations17. The disadvantage of
the inhibition of Bcl-xL is the fact that platelets are dependent on
Bcl-xL and extensive inhibition of Bcl-xL may, therefore, lead
to thrombocytopenia17. However, in patients that are predicted to
be sensitive to Bcl-xL inhibition, low platelet counts may not be a
concern since tumor cells due to a genetic alteration may be more
prone to Bcl-xL inhibition than platelets.
To elucidate the mechanisms by which IDH1 R132H-mutated
cells are more prone to Bcl-xL inhibition, we hypothesized
that these effects might be mediated by the oncometabolite,
2-HG18. Consistent with this postulate are our findings that
IDH1-mutated glioblastomas and our engineered IDH1-mutated
glioblastoma cells displayed lower levels of Mcl-1 and treatment
with a cell-permeable form of 2-HG (pharmacologically
relevant concentrations) suppressed Mcl-1 protein levels in IDH1
wild-type cells. Mechanistically, 2-HG-mediated reduction of
Mcl-1 protein levels is explained by less protein synthesis and a
partial shutdown of mTORC1 signaling19, which is in keeping
with a recent report demonstrating that 2-HG prolongs the life-
span of C. elegans in part by inhibition of mTORC1 signaling3.
While there are multiple possibilities of suppression of mTOR
signaling, 2-HG appears to interfere with oxidative phosphor-
ylation at the level of the ATP-synthase, culminating in a state
of energy depletion and suppression of mTORC1 signaling3.
Our present findings support those earlier observations since
in our model systems mutant IDH1 leads to a metabolic repro-
gramming, with a more “glycolytic” phenotype rather than
“oxidative”. As a result, both mutant IDH1 and 2-HG-treated
cells displayed lower baseline OCRs and ATP levels, which in part
mediated a reduction of protein synthesis, mTORC1 signaling
and finally a decline in Mcl-1. The precise mechanism as to how
mutant IDH1 cells become more glycolytic is likely to involve
multiple factors. In addition to the direct impact of 2-HG on
cellular respiration, effects on other important glycolytic reg-
ulatory enzymes, such as pyruvate dehydrogenase, which is at the
interface between oxidative and purely “aerobic glycolytic”
metabolism and is regulated by a complex cascade
of phosphorylation, require further analysis. Aside from its
regulation on protein synthesis, we also found that 2-HG impacts
the stability of Mcl-1 through modulation of its proteasomal
turnover. This finding is consistent with numerous other reports
that show that various compounds regulate the proteasomal
degradation of Mcl-120–23 and confirms the notion that Mcl-1 is
commonly regulated at the posttranslational level.
Our results differ mechanistically from earlier findings in
myeloid leukemia16, which did not display changes in Mcl-1
and Noxa levels in cells treated with 2-HG. However, these
observations might be cell- or tumor-type specific. For instance,
hematological malignancies might respond in a different manner
compared to solid malignancies, such as glioblastomas or
cholangiocarcinomas. We also verified by siRNA studies that
Noxa is involved in the cell death induced by Bcl-2/Bcl-xL
inhibition and 2-HG exposure, suggesting that Noxa is required
in the death and not a “bystander” effect. In agreement with
a Mcl-1/Noxa-dependent effect is our finding that 2-HG in
combination with ABT263 elicits Bak-dependent cell death since
Bak is known to primarily bind to Mcl-1, while Bax is incapable
of interacting with Mcl-1.
Finally, we demonstrated that Bcl-xL inhibition is highly
efficacious in several in vivo model systems of mutated IDH1,
including an orthotopic xenograft model of glioblastoma and a
patient-derived xenograft. These results should be seen in context
of recent observations published by others. For instance, the Lai
group demonstrated that IDH1 mutations render glioblastoma
cells more sensitive to radiation24. Interference with glutamine
metabolism or NAD + depletion led to a more pronounced
growth reduction in IDH1-mutated cells25, 26. In connection with
DNA-damaging agents, it was shown that IDH1-mutated
glioblastomas are more sensitive to a certain class of DNA
alkylating reagents27. Src inhibition causes synthetic lethality in
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IDH-mutated cholangiocarcinomas. Similarly, the c-myc
and BRD4 inhibitor, JQ1, was shown to be efficacious in
IDH1-mutated cells28. In total, these data suggest that induction
of synthetic lethality in IDH-mutated neoplasms is feasible and
potentially highly efficacious.
In summary, our work suggests that glioblastomas harboring
an IDH1 mutation might benefit from the addition of a
compound that efficiently interferes with Bcl-xL.
Methods
Ethics statement. All procedures were in accordance with Animal Welfare
Regulations and approved by the Institutional Animal Care and Use Committee
at the Columbia University Medical Center. For studies involving human samples
Columbia IRB approved these studies. For human studies, informed written
consent was obtained from all patients.
Reagents. ABT263 and ABT199 were purchased from Selleckchem (Houston, TX).
Compounds were dissolved in dimethyl sulfoxide (DMSO) and 10 mM stock
solutions were prepared and stored at −20 °C. (2 R)-2-hydroxyglutaric acid octyl
ester sodium salt was purchased from Cayman Chemical Company (Ann Arbor,
MI). A 50 mM stock solution was prepared in phosphate-buffered saline and stored
at −20 °C.
Cell cultures and growth conditions. BT-142, U87MG, T98G and LN229 human
glioblastoma cell lines were obtained from the American Type Culture Collection
(Manassas, VA) and were negatively tested for Mycoplasma. NCH612 and
NCH644 stem cell-like glioma cells were obtained from Cell Line Services (CLS,
Heidelberg, Germany) and negatively tested for Mycoplasma. HCT116 IDH1
parental (clone: 326) and HCT116 IDH1 (R132H/ + ) (clone: 97) human colorectal
cancer cells were purchased from Horizon Discovery (Cambridge, MA) and
negatively tested for mycoplasma. The identities of the cell lines we purchased were
confirmed by the respective source of purchase. SF188 pediatric glioblastoma cells
were kindly provided by Dr Craig Thompson (Memorial Sloan Kettering Cancer
Center, New York, NY). MGPP-3 (PDGF + , p53(−/−), PTEN (−/−)) are murine
proneural glioblastoma cells, which were generated by Dr Peter Canoll (Columbia
University, New York, NY). U251 glioblastoma cells were kindly provided by
Dr James Goldman (Columbia University, New York, NY). GBM12 and GBM164
glioblastoma cells were kindly provided by Dr J. Sarkaria (Mayo Clinic, Rochester,
MI). All cells were cultured as previously described29, 30. T98G, LN229, U251,
and MGPP-3 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)
with 10% fetal bovine serum (FBS), 4.5 g l−1 glucose, 4mM L-glutamine, 1 mM
pyruvate and 5 μg ml−1 PlasmocinTM for maintenance. For experimental condi-
tions these cells were cultured in DMEM containing only 1.5% FBS to mimic the
nutrition starved setting in tumors. For the culture of SF188 the fore-mentioned
medium was supplemented in addition with 2mM L-alanyl-L-glutamine (Gluta-
MAXTM-I, Gibco, Japan). NCH644 and NCH612 were cultured in MG-43 medium
(CLS, Heidelberg, Germany) for both maintenance and experiments.
Vector constructs and viral transduction. For the generation of retroviral
particles for IDH1 R132H and IDH1 wild-type we utilized the following plasmids:
pLPCX-IDH1 and pLPCX-IDH1 R132H. These plasmids were kindly provided by
Dr Albert Lai (David Geffen School of Medicine at UCLA, Los Angeles, CA)24.
In addition, we utilized lentiviral doxycycline-inducible pTRIPZ IDH1 R132H and
pTRIPZ IDH1wild-type vectors, which were kindly provided by Dr Ravindra
Majeti (Stanford University School of Medicine, Stanford, CA)16.
Cell viability assays. In order to examine cellular proliferation, 3-[4, 5-dime-
thylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) or CellTiter-Glo® assays
were performed as previously described31–33.
Measurement of apoptosis and mitochondrial membrane potential. For
annexin V staining the FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen, USA) was used according to the manufacturer’s instructions. Staining
for propidium iodide or JC-1 was performed as previously described31. The data
were analyzed with the FlowJo software (version 8.7.1; Tree Star, Ashland, OR).
Protein extraction from human brain tumor samples. Human tumor samples of
human anaplastic astrocytomas were kindly provided by Dr Peter Canoll
(Columbia University, New York, NY). To extract protein, 100–200 mg of
tumor tissue was mechanically dissociated in RIPA buffer. After incubation on
ice for 15 min, samples were centrifuged at 14,000×g for 10 min. The supernatant
was collected and sonicated 3× for 5 s each on ice prior to subsequent western
blot analyses.
Western blot analysis. Specific protein expression in cell lines was determined by
western blot analysis as described before33, 34 using the following primary anti-
bodies: Mcl-1 (1:500; #5453 CST: Cell Signaling Technology, Danvers, MA), Bcl-2
(1:500; #4223 CST), mutation specific IDH1 R132H antibody (1:250;
#DIA-H09 Dianova GmbH, Hamburg, Germany), human caspase-9 (1:1,000;
#9502 CST), cleaved caspase-3 (1:250; #9664 CST), total PARP (1:1000; #9532
CST), cleaved PARP (Asp214, 1:1000; #9541 CST), Bcl-xL (1:500; #2764 CST),
Bim (1:500; #2933 CST), Bak (1:500; #6947 CST) Noxa (1:500, clone 114C307;
Calbiochem), β-actin (1:8,000, clone AC15; A1978 Sigma Aldrich), Vinculin
(1:1000, #ab129002 Abcam). Secondary HRP-linked antibodies were purchased
from Santa Cruz Biotechnology.
Capillary electrophoresis was performed on the Wes simple instrument
(Protein simple, San Jose, CA) using the 12–230 kDa Wes separation module
and anti-rabbit or anti-mouse detection modules according to the manufacturer’s
instructions. Antibody concentrations are available on the Protein simple website.
Uncropped western blot and capillary electrophoresis data are shown in
Supplementary Fig. 9.
Metabolic flux analysis. For the determination of OCR and ECAR, the Seahorse
XFp Flux analyzer was utilized in accordance with the manufacturer instructions
and published protocols for the indicated cell lines.
Sunset assay. To determine effects on protein synthesis a non-radioactive
puromycin-based assay was used5. For this assay, cells were treated for 2 h
with puromycin at a concentration of 10 μg ml−1. Afterwards, whole-cell extracts
were harvested and western blot analysis was performed using anti-puromycin
(1:10,000, clone 12D10; EMD Millipore). Cells treated with cycloheximide at a
concentration of 10 μg ml−1 served as negative control.
Transfections of siRNAs. Non-targeting siRNA-pool (ON-TARGETplus
Non-targeting Pool, # D-001810-10-05) and Mcl-1 (SMARTpool:
ON-TARGETplus Mcl-1 siRNA, L-004501-00-0005) were purchased from
Dharmacon and transfected as previously described21, 35. For single siRNA
experiments involving Mcl-1, the following sequences were employed: siRNA-1:
GGU UUG GCA UAU CUA AUA A; siRNA-2: GAA GGU GGC AUC AGG AAU
G, siRNA-3: GAU UAU CUC UCU CGG UAC CUU, siRNA-4: CGA AGG AAG
UAU CGA AUU U (Dharmacon). For siRNA experiments, involving Bcl-xL,
siRNAs were either used from Ambion (Silencer® Select s1920; AUA CUU UUG
UGG AAC UCU ATT) or Cell Signaling Technology® (Signal silence® Bcl-xL
siRNA I; #6362). Silencing of PMAIP1 was performed using Silencer® Select
siRNA-1 (s10708; AGA UAU GAA UGU UUC UAA ATT) and siRNA-2
(s10709; AGU CGA GUG UGC UAC UCA ATT) from Ambion. BAK1 knock-
down was performed using Silencer® Select s1880 from Ambion. Briefly, cells
were incubated for 6 h with the formed complexes of Oligofectamine® 2000
(Invitrogen, Carlsbad, CA) and the respective siRNA (12-well condition) in
DMEM without FBS and antibiotics. After 6 h, FBS was added to a total
concentration of 1.5%.
Microarray and GSEA analysis. Affymetrix Human Gene 2.0 ST microarrays
were utilized to assess the transcriptome for U87MG IDH1 wild-type vs. IDH1
R132H. To obtain gene-level expression values, the affy package (version 1.36.1)
was utilized. The genes on the array were assigned their respective Entrez Gene
identifiers. The log2-transformed fold changes between the different groups
(IDH1 wild-type vs. IDH1 mutant) were ranked. The rank-lists served as the source
for gene set enrichment analysis (GSEA, version 2.2.1), utilizing gene sets available
from the Molecular Signatures Database, version 5.036, 37.
Real-time rtPCR and cDNA synthesis. Real-time rtPCR was performed as
described before38 using the primers as outlined in Supplementary Table 3.
Subcutaneous xenograft model. In all, 1 × 106 U87MG/HCT116 IDH1-WT/
IDH1-R132H cells suspended in Matrigel (1:1) or IDH1-mutant GBM164 cryo-
mush were implanted subcutaneously into the flanks of 6–8-week-old SCID SHO
mice as previously described20, 39. Treatment was performed intraperitoneally 3×
per week for 2 weeks for U87MG or for 1 week for HCT116 and GBM164. The
GBM164 is a patient-derived xenograft (PDX) from a 38-year-old female with a
glioblastoma, harboring mutated IDH (R132H) (WHO 2007 classification). For
intraperitoneal application ABT263 was dissolved in 80% Cremophor EL (SIGMA,
St. Louis, MO) and 20% Ethanol (Pharmco-Aaper, Brookfield, CT) (v/v).
Orthotopic transgenic glioblastoma and convection-enhanced delivery model.
The study was approved by the Institutional Animal Care and Use Committee at
the Columbia University Medical Center. PDGF-IRES-Cre virus was stereo-
tactically injected into 6–8-week-old male or female transgenic mice (PTENflox/flox,
p53flox/flox, luciferasestop-flox) weighing 20 to 30 g as previously described6, 7. A burr
hole was positioned 2 mm anterior and 2 mm lateral of the bregma prior to
introducing a Hamilton syringe under stereotactic guidance 2 mm into the rostral
subcortical white matter. Motorized injections of the retrovirus were performed at
a rate of 0.2 μl min−1.
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Convection-enhanced delivery was performed as described before40. Five days
after implantation of tumor cells, alzet® micro-osmotic pumps (DURECT
Corporation, Cupertino, CA) were implanted for a 7-day long continuous
intracranial infusion of 2-HG or solvent. To verify intracranial drug administration
1% Gadolinium was added to the pumps (Omniscan, GE Healthcare Inc.,
Princeton, NJ) and MRIs (Bruker ICONTM, 1 Tesla or Bruker BioSpecTM, 9.4
Tesla) were performed after removal of the pump system. Survival was assessed by
calculating Kaplan–Meier curves. Bioluminescent imaging was performed as
described in refs 6, 7.
Statistical analysis. Statistical significance was assessed by Student t-test
using Prism version 5.04 (GraphPad, La Jolla, CA). All tests were two-sided.
A p ≤ 0.05 was considered statistically significant. The CompuSyn software
(ComboSyn, Inc., Paramus, NJ—www.combosyn.com last accessed 06/01/15)
was used for the drug combination analysis including the calculation of the
combination index (CI) and isobologram. A CI< 1 was considered as synergistic,
a CI= 1 as additive and a CI> 1 as antagonistic. The concentration for each
compound resulting in 50% inhibition (ED50) is normalized to 1, plotted on
x- or y-axis and connected by a line, which represents the ED50 isobologram.
Data points of drug combinations plotted below the connecting line represent
a synergistic interaction, data points located on the line represent an additive
interaction and data points located above the connecting line represent an
antagonistic interaction.
Data availability. The authors declare that the data within this manuscript are
available in the main and/or supplementary figures or from the corresponding
author upon reasonable request.
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